Atypical Hemolytic Uremic Syndrome Clinical Trial
— COMMUTE-pOfficial title:
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
Status | Recruiting |
Enrollment | 45 |
Est. completion date | September 16, 2029 |
Est. primary completion date | December 12, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 28 Days to 17 Years |
Eligibility | Inclusion Criteria: - Body weight >= 5 kg at screening. - Vaccination against Neisseria meningitis serotypes A, C, W, and Y; vaccination against serotype B, according to national vaccination recommendations. - Vaccination against Haemophilus influenzae type B and Streptococcus pneumoniae, according to national vaccination recommendations. - For patients continuing to receive other therapies concomitantly with crovalimab (e.g., immunosuppressants, corticosteroids, mammalian target of rapamycin inhibitor (mTORi), or calcineurin inhibitors): stable dose for >=28 days prior to screening and up to the first crovalimab administration. - For female participants of childbearing potential: an agreement to remain abstinent or use contraception. - Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant. - Onset of initial TMA presentation within 28 days prior to the first dose of crovalimab (for Naive Cohort only). - Documented treatment with either eculizumab or ravulizumab (for Switch Cohort only). - Clinical evidence of response to a C5 inhibitor (for Switch Cohort only). - Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP participants in the Pretreated Cohort only). - Known C5 polymorphism (for C5 SNP participants in the Pretreated Cohort only). Exclusion Criteria: - TMA associated with non-aHUS related renal disease. - Positive direct Coombs test. - Chronic dialysis within 90 days prior to first crovalimab administration , and /or end stage renal disease - Identified drug exposure-related TMA. - Presence or history of a condition that could trigger TMA, such as malignancy, bone marrow or organ transplant (other than kidney transplant) or autoimmune disease. - History of a kidney disease, other than aHUS. - History of Neisseria meningitidis infection within 6 months of study enrollment. - Known or suspected immune deficiency (e.g., history of frequent recurrent infections). - Positive HIV test. - Active systemic bacterial, viral, or fungal infection within 14 days before first crovalimab administration. - Presence of fever (>= 38°C) within 7 days before the first crovalimab administration. - Multi-system organ dysfunction or failure. - Recent intravenous immunoglobulin (IVIg) treatment. - Pregnant or breastfeeding or intending to become pregnant. - Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater. - Recent use of tranexamic acid. - Current or previous treatment with a complement inhibitor (for Naive Cohort only). - First initiation of plasma exchange/plasma infusions (PE/PI) should not be more than 28 days prior to first crovalimab administration (for Naive Cohort only). - Last PE/PI completed less than 2 hours prior to first crovalimab administration (for Naive Cohort only). - Receiving PE/PI within 8 weeks of the first crovalimab administration (Switch Cohort only). - Positive for active Hepatitis B and/or C infections (HBV/HCV) (for Switch Cohort and switching C5 SNP Pretreated Cohort participants who recently received C5 inhibitor treatment). - Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment). - Documented condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC)-TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect and TMA related to Diacylglycerol kinase e (DGKE) nephropathy. |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Gent | Gent | |
Belgium | UZ Leuven Gasthuisberg | Leuven | |
Belgium | CHC MontLégia | Liege | |
Brazil | Santa Casa de Belo Horizonte; Centro de Hemodiálise | Belo Horizonte | MG |
Brazil | UPECLIN Hospital das Clinicas da Faculdade de Medicina de Botucatu | Botucatu | SP |
Brazil | Inst. Da Criança- Faculdade de Medicina Usp; Unidade de Pneumologia | Sao Paulo | SP |
Canada | CHU Sainte-Justine | Montreal | Quebec |
China | Beijing Children's Hospital, Capital Medical University | Beijing City | |
China | Peking University First Hospital | Beijing City | |
China | The children's hospital , Zhejiang university school of medicine | Hangzhou City | |
China | Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech | Wuhan | |
France | Hôpital Arnaud de Villeneuve; Néphrologie pédiatrique | Montpellier | |
France | Gh Necker Enfants Malades; Nephrologie | Paris | |
France | Hôpital Robert Debré; Nephrologie pediatrique | Paris | |
France | CHU de Toulouse - Hôpital des Enfants; Nephro - Rhumato - Medecine Interne - Hypertension | Toulouse | |
Hungary | Szegedi Tudományagyetem; Gyermekgyógyászati Klinika | Szeged | |
India | Medanta-The Medicity | Gurgaon | Haryana |
India | All India Institute Of Medical Sciences (AIIMS) | New Delhi | Delhi |
Israel | Rambam medical Center; Pediatric Nephrology | Haifa | |
Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Nefrologia Pediatrica | Milano | Lombardia |
Japan | Aichi Children?s Health and Medical Center | Aichi | |
Japan | Chiba Children's Hospital | Chibashi, Chibaken | |
Japan | Hiroshima Prefectural Hospital | Hiroshima | |
Japan | Yokohama City University Medical Center | Kanagawa | |
Japan | Okinawa Prefectural Nanbu Medical Center & Children's Medical Center | Okinawa | |
Mexico | Hospital de Especialidades Puerta de Hierro S.A de C.V. | Zapopan | Jalisco |
Poland | Uniwersyteckie Centrum Kliniczne; Klinika Chorob Nerek i Nadci?nienia Dzieci i Mlodziezy | Gdansk | |
Poland | Instytut ?Centrum Zdrowia Matki Polki; Klinika Pediatrii i Immunologii i Nefrologii | Lodz | |
Poland | Instytut Pomnik-Centrum Zdrowia Dziecka, Klinika Nefrologii, Transp. Nerek i Nadcisnienia Tetniczego | Warszawa | |
Poland | Szpital Kliniczny nr 1 im. prof. Szyszko; Oddz. Nefrologii Dzieciecej z Pododdzia?em Dializoterapii | Zabrze | |
South Africa | Red Cross War Memorial Children's Hospital; Pediatric Nephrology | Rondebosch | |
Spain | Hospital Universitario Virgen del Rocío | Sevilla | |
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | Cincinnati Children's Hospital Medical Center; Investigational Drug Services | Cincinnati | Ohio |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Memorial Healthcare Systems | Hollywood | Florida |
United States | University of Nebraska; Pediatric Nephrology | Omaha | Nebraska |
United States | University of California Davis Medical Center; Gi and Hepatology | Sacramento | California |
United States | University Of Utah Hosp & Clin; Investigational Pharmacy | Salt Lake City | Utah |
United States | UT Health Science Center; SouthTexas Pediatric Blood and Cancer Ctr | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche | Chugai Pharmaceutical |
United States, Belgium, Brazil, Canada, China, France, Hungary, India, Israel, Italy, Japan, Mexico, Poland, South Africa, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants with complete TMA response (cTMAr) (Naive Cohort only) | Baseline up to Week 25 | ||
Secondary | Change from Baseline in Dialysis Status | Baseline up to Week 25 | ||
Secondary | Change in Estimated Glomerular Filtration Rate (eGFR) (Naive and Switch Cohorts) | Baseline up to Week 25 | ||
Secondary | Percentage of Participants with Change from Baseline in Chronic Kidney Disease (CKD) stage (Naive and Switch Cohorts) | Baseline up to Week 25 | ||
Secondary | Observed Value in Platelet Count (Naive and Switch Cohorts) | Baseline up to Week 25 | ||
Secondary | Observed Value in Lactate Dehydrogenase (LDH) (mg/dL) (Naive and Switch Cohorts) | Baseline up to Week 25 | ||
Secondary | Observed Value in Hemoglobin (mg/dL) (Naive and Switch Cohorts) | Baseline up to Week 25 | ||
Secondary | Change from Baseline in Platelet Count (Naive and Switch Cohorts) | Baseline up to Week 25 | ||
Secondary | Change from Baseline in Lactate Dehydrogenase (LDH) (mg/dL) (Naive and Switch Cohorts) | Baseline up to Week 25 | ||
Secondary | Change from Baseline in Hemoglobin (mg/dL) (Naive and Switch Cohorts) | Baseline up to Week 25 | ||
Secondary | Percentage of Participants with Platelet Count >= LLN (Naive Cohort only) | Baseline up to Week 25 | ||
Secondary | Percentage of Participants with Normalisation of LDH (i.e., =< Upper Limit Normal (ULN)) (Naive Cohort only) | Baseline up to Week 25 | ||
Secondary | Percentage of Participants with >=25% decrease in Serum Creatinine (Naive Cohort only) | Baseline up to Week 25 | ||
Secondary | Time to complete TMA response (cTMAr) (Naive Cohort only) | Up to 8 years | ||
Secondary | Duration of complete TMA response (cTMAr) (Naive Cohort only) | Up to 8 years | ||
Secondary | Percentage of Participants with complete TMA response (cTMAr) (Naive Cohort only) | Week 25 | ||
Secondary | Percentage of Participants with maintained TMA control (mTMAc) (Switch Cohort only) | Baseline through Week 25 | ||
Secondary | Percentage of Participants with Adverse Events (AEs) | Up to 8 years | ||
Secondary | Percentage of Participants with Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension (including malignant renal hypertension) and Infections (including meningococcal meningitis) | Up to 8 years | ||
Secondary | Percentage of Participants with Adverse Events (AEs) leading to Study Drug Discontinuation | Up to 8 years | ||
Secondary | Percentage of Participants with Clinical Manifestations of Drug-Target-Drug Complex (DTDC) formation amongst participants who switched to crovalimab treatment from eculizumab/ravulizumab treatment (Switch Cohort and switching Pretreated participants) | Up to Week 25 | ||
Secondary | Serum Concentrations of Crovalimab over time | Up to 8 years | ||
Secondary | Percentage of Participants with Anti-Crovalimab Antibodies | Up to 8 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Withdrawn |
NCT03303313 -
A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
|
Phase 2 | |
Recruiting |
NCT04861259 -
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 3 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Terminated |
NCT02614898 -
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
|
||
Completed |
NCT02574403 -
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS
|
Phase 4 | |
Recruiting |
NCT05795140 -
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
|
Phase 3 | |
Completed |
NCT00844844 -
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
|
Phase 2 | |
Completed |
NCT00844545 -
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
|
Phase 2 | |
Terminated |
NCT01522170 -
aHUS Observational Long Term Follow-Up
|
N/A | |
Terminated |
NCT02464891 -
Complement Inhibition in aHUS Dialysis Patients
|
Phase 2 | |
Withdrawn |
NCT02626663 -
The Role of Microparticles as a Biomarker
|
||
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Completed |
NCT00838513 -
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 2 | |
Completed |
NCT00844428 -
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
|
Phase 2 | |
Withdrawn |
NCT03999840 -
Eculizumab to Cemdisiran Switch in aHUS
|
Phase 2 | |
Recruiting |
NCT04889430 -
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
|
Phase 3 | |
Recruiting |
NCT05935215 -
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
|
Phase 3 | |
Recruiting |
NCT03205995 -
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
|
Phase 3 | |
Recruiting |
NCT05996731 -
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
|
N/A |